Flavia Borellini
Direktor/Vorstandsmitglied bei REVOLUTION MEDICINES, INC.
Vermögen: 407 256 $ am 31.05.2024
Profil
Flavia Borellini is an Independent Director at Cantargia AB, Revolution Medicines, Inc., and Viracta Therapeutics, Inc. She is also a Director at Kartos Therapeutics, Inc. and a Member of Roche Group.
Previously, she served as the Chief Executive Officer at Acerta Pharma BV from 2016 to 2019, VP-Global Product & Portfolio Strategy at AstraZeneca PLC from 2018 to 2020, and Vice President-Program Leadership at Onyx Pharmaceuticals, Inc. from 2012 to 2013.
Dr. Borellini holds a doctorate degree from Università degli Studi di Modena e Reggio Emilia.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2024 | 10 625 ( 0,01% ) | 407 256 $ | 31.05.2024 | |
| 22.04.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Flavia Borellini
| Unternehmen | Position | Beginn |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Direktor/Vorstandsmitglied | 22.06.2021 |
| VIRACTA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 14.08.2021 |
| CANTARGIA AB | Direktor/Vorstandsmitglied | 01.10.2020 |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Direktor/Vorstandsmitglied | 01.02.2018 |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Flavia Borellini
| Unternehmen | Position | Ende |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | 01.01.2020 |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Vorstandsvorsitzender | 01.02.2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01.10.2013 |
Ausbildung von Flavia Borellini
| Università degli Studi di Modena e Reggio Emilia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| REVOLUTION MEDICINES, INC. | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| CANTARGIA AB | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
